During the last session, Kyverna Therapeutics Inc. (NASDAQ:KYTX)’s traded shares were 0.76 million. At the end of the trading day, the stock’s price was $5.25, reflecting an intraday gain of 15.38% or $0.7. The 52-week high for the KYTX share is $35.06, that puts it down -567.81 from that peak though still a striking 16.19% gain since the share price plummeted to a 52-week low of $4.40. The company’s market capitalization is $226.54M, and the average intraday trading volume over the past 10 days was 0.39 million shares, and the average trade volume was 423.21K shares over the past three months.
Kyverna Therapeutics Inc. (KYTX) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.29. KYTX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.79.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kyverna Therapeutics Inc. (NASDAQ:KYTX) trade information
Kyverna Therapeutics Inc. (KYTX) registered a 15.38% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 15.38% in intraday trading to $5.25, hitting a weekly high. The stock’s 5-day price performance is 13.39%, and it has moved by -24.89% in 30 days. The short interest in Kyverna Therapeutics Inc. (NASDAQ:KYTX) is 2.27 million shares and it means that shorts have 5.81 day(s) to cover.
Kyverna Therapeutics Inc. (KYTX) estimates and forecasts
Statistics show that Kyverna Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Kyverna Therapeutics Inc. (KYTX) shares have gone down -76.95% during the last six months, with a year-to-date growth rate more than the industry average at 96.22% against 17.50.
While earnings are projected to return 96.24% in 2024.
KYTX Dividends
Kyverna Therapeutics Inc. is due to release its next quarterly earnings on 2024-Aug-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Also, the Mutual Funds coming in first place with the largest holdings of Kyverna Therapeutics Inc. (KYTX) shares are JP Morgan Small Cap Growth Fund and Vanguard Total Stock Market Index Fund . Data provided on Jun 30, 2024 indicates that JP Morgan Small Cap Growth Fund owns about 1.05 shares. This amounts to just over 2.43 percent of the company’s overall shares, with a $5.5 million market value. The same data shows that the other fund manager holds slightly less at 633.84, or about 1.47% of the stock, which is worth about $3.33 million.
